

Jos Beijnen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7237587/jos-beijnen-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

132
papers

4,020
citations

29
h-index

60
g-index

138
ext. papers

4,767
ext. citations

5
avg, IF

5.32
L-index

#	Paper	IF	Citations
132	Development and validation of an LC-MS/MS assay for the quantification of cintirorgon (LYC-55716) in mouse plasma and tissue homogenates. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022 , 207, 114421	3.5	0
131	Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022 , 207, 114402	3.5	1
130	Optimized sample pre-treatment procedure for the simultaneous UPLC-MS/MS quantification of ipilimumab, nivolumab, and pembrolizumab in human serum.. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2022 , 1196, 123215	3.2	0
129	ABCB1 limits brain exposure of the KRAS inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability.. <i>Pharmacological Research</i> , 2022 , 178, 106137	10.2	0
128	ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites. <i>Pharmacological Research</i> , 2021 , 105954	10.2	1
127	ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability. <i>Pharmaceutics</i> , 2021 , 13,	6.4	2
126	ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 1173-1182	6.1	5
125	Bioanalysis of erlotinib, its O-demethylated metabolites OSI-413 and OSI-420, and other metabolites by liquid chromatography-tandem mass spectrometry with additional ion mobility identification. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1166, 122554	3.2	2
124	The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclib. <i>European Journal of Pharmaceutical Sciences</i> , 2021 , 159, 105740	5.1	2
123	Development and Validation of a Stability-indicating HPLC Method for the Analysis of Cabazitaxel in Jevtana [®] Concentrate-solvent Leftover Samples. <i>Current Pharmaceutical Analysis</i> , 2021 , 17, 691-701	0.6	
122	The development and validation of a high performance liquid chromatography method to determine the radiochemical purity of [Lu]Lu-HA-DOTA-TATE in pharmaceutical preparations. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1174, 122718	3.2	1
121	Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1174, 122718	3.2	7
120	Extrahepatic metabolism of ibrutinib. <i>Investigational New Drugs</i> , 2021 , 39, 1-14	4.3	4
119	Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Value in Health</i> , 2021 , 24, 121-128	3.3	1
118	Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021 , 203, 114225	3.5	3
117	Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021 , 205, 114319	3.5	
116	ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib. <i>Pharmacological Research</i> , 2021 , 172, 105850	10.2	1

115	The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: A scoping review. <i>Drug and Alcohol Dependence</i> , 2021 , 227, 108984	4.9	3
114	Chromatographic bioanalytical assays for targeted covalent kinase inhibitors and their metabolites. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1162, 122466	3.2	1
113	Skin tissue sample collection, sample homogenization, and analyte extraction strategies for liquid chromatographic mass spectrometry quantification of pharmaceutical compounds. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 191, 113590	3.5	2
112	Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020 , 1147, 122121	3.2	4
111	Bioanalytical method for the simultaneous quantification of irinotecan and its active metabolite SN-38 in mouse plasma and tissue homogenates using HPLC-fluorescence. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020 , 1149, 122177	3.2	2
110	OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation. <i>British Journal of Pharmacology</i> , 2020 , 177, 3060-3074	8.6	8
109	Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose. <i>Clinical Pharmacology in Drug Development</i> , 2020 , 9, 929-937	2.3	1
108	Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice. <i>International Journal of Pharmaceutics</i> , 2020 , 581, 119277	6.5	6
107	Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. <i>European Journal of Cancer</i> , 2020 , 130, 32-38	7.5	5
106	Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020 , 1144, 122098	3.2	3
105	Highly sensitive UPLC-MS/MS method for the quantification of paromomycin in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 185, 113245	3.5	4
104	Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases. <i>Neurology</i> , 2020 , 94, e521-e528	6.5	18
103	P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). <i>International Journal of Pharmaceutics</i> , 2020 , 573, 118842	6.5	8
102	Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice. <i>European Journal of Cancer</i> , 2020 , 136, 140-148	7.5	8
101	Development and validation of an LC-MS/MS method for the quantitative analysis of milciclib in human and mouse plasma, mouse tissue homogenates and tissue culture medium. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 190, 113516	3.5	1
100	Quantitative LC-MS/MS analysis of 5-hydroxymethyl-2 α -deoxyuridine to monitor the biological activity of J-binding protein. <i>Analytical Biochemistry</i> , 2020 , 610, 113930	3.1	
99	Neoadjuvant Systemic Treatment of Primary Angiosarcoma. <i>Cancers</i> , 2020 , 12,	6.6	7
98	Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials. <i>Journal of Geriatric Oncology</i> , 2020 , 11, 529-532	3.6	

97	Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019 , 136, 120-130	5.7	10
96	Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2019 , 411, 5331-5345	4.4	23
95	Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1980-1981	2.2	12
94	Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). <i>Pharmacological Research</i> , 2019 , 146, 104297	10.2	14
93	Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019 , 1122-1123, 78-82	3.2	4
92	LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 170, 161-168	3.5	11
91	Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort. <i>Cancer Medicine</i> , 2019 , 8, 1406-1415	4.8	11
90	Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019 , 1110-1111, 116-123	3.2	7
89	Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite Eddecitabine in human plasma, whole blood and urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019 , 1109, 132-141	3.2	7
88	Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice. <i>Drugs and Aging</i> , 2019 , 36, 379-385	4.7	4
87	Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e893-e896	3.3	
86	Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 174, 561-566	3.5	18
85	Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study. <i>Pharmaceutical Research</i> , 2019 , 36, 181	4.5	3
84	Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e383-e386	3.3	5
83	A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. <i>European Journal of Cancer</i> , 2019 , 107, 60-67	7.5	30
82	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice. <i>International Journal of Pharmaceutics</i> , 2019 , 556, 172-180	6.5	5
81	Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 164, 128-134	3.5	29
80	Development, validation, and clinical application of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of total intracellular Eddecitabine nucleotides and genomic DNA incorporated Eddecitabine and 5-methyl-2'-deoxycytidine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 164, 16-26	3.5	4

79	Solubility and bioavailability improvement of pazopanib hydrochloride. <i>International Journal of Pharmaceutics</i> , 2018 , 544, 181-190	6.5	10
78	Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018 , 1083, 204-208	3.2	10
77	A multi-gram-scale stereoselective synthesis of Z-endoxifen. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018 , 28, 1352-1356	2.9	4
76	Thermal stability study of crystalline and novel spray-dried amorphous nilotinib hydrochloride. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018 , 148, 182-188	3.5	6
75	P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. <i>International Journal of Cancer</i> , 2018 , 143, 2029-2038	7.5	17
74	Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018 , 161, 136-143	3.5	14
73	Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2. <i>Neoplasia</i> , 2018 , 20, 710-720	6.4	44
72	EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid. <i>Journal of Neuro-Oncology</i> , 2018 , 137, 1-10	4.8	21
71	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice. <i>Pharmacological Research</i> , 2018 , 129, 414-423	10.2	18
70	P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability. <i>Pharmacological Research</i> , 2018 , 137, 47-55	10.2	15
69	P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton α Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability. <i>Molecular Pharmaceutics</i> , 2018 , 15, 5124-5134	5.6	9
68	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. <i>Lancet Oncology, The</i> , 2018 , 19, 1459-1467	21.7	139
67	Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018 , 1102-1103, 167-172	3.2	9
66	Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy. <i>Breast</i> , 2018 , 42, 38-40	3.6	17
65	Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018 , 1090, 14-21	3.2	19
64	Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. <i>Pharmacological Research</i> , 2017 , 120, 43-50	10.2	36
63	A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir. <i>European Journal of Cancer</i> , 2017 , 86, 217-225	7.5	18
62	An LC-MS/MS method for quantification of the active abiraterone metabolite (4)-abiraterone (D4A) in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017 , 1068-1069, 119-124	3.2	11

61	Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium. <i>European Journal of Cancer</i> , 2017 , 85, 78-85	7.5	3
60	Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2). <i>Molecular Pharmaceutics</i> , 2017 , 14, 3258-3268	5.6	14
59	Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017 , 1061-1062, 300-305	3.2	7
58	Improving the solubility of nilotinib through novel spray-dried solid dispersions. <i>International Journal of Pharmaceutics</i> , 2017 , 529, 294-302	6.5	18
57	Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 130, 244-263	3.5	24
56	Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. <i>European Journal of Cancer</i> , 2016 , 54, 120-130	7.5	29
55	EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors. <i>Neuro-Oncology</i> , 2016 , 18, 855-62	1	39
54	Crizotinib-induced fatal fulminant liver failure. <i>Lung Cancer</i> , 2016 , 93, 17-9	5.9	20
53	Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016 , 1012-1013, 118-23	3.2	16
52	Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. <i>Journal of Clinical Oncology</i> , 2016 , 34, 227-34	2.2	181
51	Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 118, 123-131	3.5	29
50	Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. <i>Cancers</i> , 2016 , 8,	6.6	22
49	Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016 , 1023-1024, 24-9	3.2	8
48	Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 126, 75-82	3.5	27
47	Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?. <i>Cancer Treatment Reviews</i> , 2016 , 50, 23-34	14.4	56
46	Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016 , 1033-1034, 390-398	3.2	23
45	Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel. <i>International Journal of Pharmaceutics</i> , 2016 , 511, 765-73	6.5	29
44	Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016 , 1031, 80-85	3.2	29

43	Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). <i>Pharmaceutical Research</i> , 2015 , 32, 2205-16	4.5	41
42	Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 107, 403-8	3.5	3
41	Gastric bypass may promote weight loss in overweight partners. <i>Journal of the American Board of Family Medicine</i> , 2015 , 28, 90-6	1.6	6
40	Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. <i>British Journal of Cancer</i> , 2015 , 113, 396-402	8.7	36
39	Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 110, 58-66	3.5	23
38	Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. <i>Pharmacology Research and Perspectives</i> , 2015 , 3, e00131	3.1	84
37	Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology, The</i> , 2015 , 16, 1639-50	21.7	190
36	Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). <i>Pharmacological Research</i> , 2015 , 102, 200-7	10.2	52
35	Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015 , 4, 374-85	4.5	17
34	Systematic review of biomarkers to monitor therapeutic response in leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1-14	5.9	42
33	Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective. <i>Clinical Breast Cancer</i> , 2015 , 15, 241-4	3	17
32	Variability in bioavailability of small molecular tyrosine kinase inhibitors. <i>Cancer Treatment Reviews</i> , 2015 , 41, 412-22	14.4	76
31	Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015 , 4, 386-95	4.5	12
30	Treatment Individualization in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015 , 11, 335-344	1	13
29	The use of combinations of monoclonal antibodies in clinical oncology. <i>Cancer Treatment Reviews</i> , 2015 , 41, 859-67	14.4	52
28	A flexed posture in elderly patients is associated with impairments in postural control during walking. <i>Gait and Posture</i> , 2014 , 39, 767-72	2.6	49
27	P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice. <i>Clinical Cancer Research</i> , 2014 , 20, 3133-45	12.9	23
26	Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 92, 144-8	3.5	1

25	Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy. <i>BioMed Research International</i> , 2014 , 2014, 897216	3	15
24	ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 2703-13	12.9	83
23	Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. <i>International Journal of Cancer</i> , 2014 , 134, 1484-94	7.5	106
22	Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 90, 7-14	3.5	14
21	Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012 , 81, 664-71	4.6	21
20	A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011 , 879, 2984-90	3.2	36
19	The pharmacokinetics of 124I-rituximab in patients with rheumatoid arthritis. <i>Human Antibodies</i> , 2011 , 20, 7-14	1.3	4
18	The pharmacokinetics of 131I-rituximab in a patient with CD20 positive Non-Hodgkin Lymphoma: Evaluation of the effect of radioiodination on the biological properties of rituximab. <i>Human Antibodies</i> , 2011 , 20, 37-40	1.3	2
17	CD20 antigen imaging with 124I-rituximab PET/CT in patients with rheumatoid arthritis. <i>Human Antibodies</i> , 2011 , 20, 29-35	1.3	23
16	Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). <i>International Journal of Pharmaceutics</i> , 2011 , 420, 244-50	6.5	78
15	Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 90, 126-32	6.1	30
14	Novel clinical trial designs for innovative therapies. <i>Clinical Pharmacology and Therapeutics</i> , 2009 , 85, 212-6	6.1	1
13	PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 83, 829-39	6.1	21
12	Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. <i>Journal of Clinical Investigation</i> , 2007 , 117, 3583-92	15.9	188
11	Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. <i>Clinical Cancer Research</i> , 2006 , 12, 5786-93	12.9	105
10	SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity. <i>Cancer Biomarkers</i> , 2006 , 2, 235-48	3.8	14
9	Are Adverse Events of Nevirapine and Efavirenz Related to Plasma Concentrations?. <i>Antiviral Therapy</i> , 2005 , 10, 489-498	1.6	104
8	Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study. <i>Antiviral Therapy</i> , 2005 , 10, 145-155	1.6	63

7	Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. <i>Oncologist</i> , 2002 , 7, 516-30	5.7	96
6	The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 15649-54	11.5	693
5	Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1160-6	2.2	188
4	Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy. <i>British Journal of Clinical Pharmacology</i> , 2001 , 51, 61-70	3.8	19
3	Phase I and pharmacokinetic study of oral paclitaxel. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2468-75	2.2	74
2	The Role of ABC Transporters at the Intestinal Barrier385-409		
1	Clinical Relevance: DrugDrug Interactions, Pharmacokinetics, Pharmacodynamics, and Toxicity747-880		4